Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Por Pal, Sumanta Kumar, Twardowski, Przemyslaw, Sartor, Oliver
Publicado em 2010

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis

Por Pal, Sumanta K., Jones, Jeremy O., Carmichael, Courtney, Saikia, Junmi, Hsu, Joanne, Liu, Xueli, Figlin, Robert A., Twardowski, Przemyslaw, Lau, Clayton
Publicado em 2012

Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Por Twardowski, Przemyslaw, Stadler, Walter M, Frankel, Paul, Lara, Primo N, Ruel, Christopher, Chatta, Gurkamal, Heath, Elisabeth, Quinn, David I, Gandara, David R
Publicado em 2010

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study

Por Lara, Primo N., Longmate, Jeff, Evans, Christopher P., Quinn, David I., Twardowski, Przemyslaw, Chatta, Gurkamal, Posadas, Edwin, Stadler, Walter, Gandara, David R.
Publicado em 2009

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy

Por Twardowski, Przemyslaw W., Beumer, Jan H., Chen, C.S., Kraft, Andrew S., Chatta, Gurkamal S., Mitsuhashi, Masato, Ye, Wei, Christner, Susan M., Lilly, Michael B.
Publicado em 2013

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: Clinical outcome and quality of life in long-term survivors

Por Pal, Sumanta K., Yamzon, Jonathan, Sun, Virginia, Carmichael, Courtney, Saikia, Junmi, Ferrell, Betty, Frankel, Paul, Hsu, JoAnn, Twardowski, Przemyslaw, Stein, Cy A., Margolin, Kim
Publicado em 2012

Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma

Por Pal, Sumanta K., Hsu, JoAnn, Hsu, Sarah, Hu, Jensen, Bergerot, Paulo, Carmichael, Courtney, Saikia, Junmi, Liu, Xueli, Lau, Clayton, Twardowski, Przemyslaw, Figlin, Robert A., Yuh, Bertram E.
Publicado em 2012

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spina...

Por Morgan, Robert J., Synold, Timothy, Mamelak, Adam, Lim, Dean, Al-Kadhimi, Zaid, Twardowski, Przemyslaw, Leong, Lucille, Chow, Warren, Margolin, Kim, Shibata, Stephen, Somlo, George, Yen, Yun, Frankel, Paul, Doroshow, James H.
Publicado em 2010

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin

Por Gately, Stephen, Twardowski, Przemyslaw, Stack, M. Sharon, Cundiff, Deborah L., Grella, Davida, Castellino, Francis J., Enghild, Jan, Kwaan, Hau C., Lee, Francis, Kramer, Robert A., Volpert, Olga, Bouck, Noel, Soff, Gerald A.
Publicado em 1997

Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421

Por Lara, Primo N., Ely, Benjamin, Quinn, David I., Mack, Philip C., Tangen, Catherine, Gertz, Erik, Twardowski, Przemyslaw W., Goldkorn, Amir, Hussain, Maha, Vogelzang, Nicholas J., Thompson, Ian M., Van Loan, Marta D.
Publicado em 2014

Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer

Por Galsky, Matthew D, Noah, Hahn, Starodub, Alexander, Hauke, Ralph J, Twardowski, Przemyslaw, Fleming, Mark, Qi, Jingjing, Sonpavde, Guru, Patel, Manishkumar, Zhu, Jun, Chippada-Venkata, Uma, Albany, Costantine, Wang, Li, Merad, Miriam, Oh, William, Bhardwaj, Nina, Gnjatic, Sacha, Kim-Schulze, Seunghee
Publicado no J Immunother Cancer (2015)

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Por Quinn, David I., Tangen, Catherine M., Hussain, Maha, Lara, Primo N., Goldkorn, Amir, Moinpour, Carol M., Garzotto, Mark G., Mack, Philip C., Carducci, Michael A., Monk, J. Paul, Twardowski, Przemyslaw W., Van Veldhuizen, Peter J., Agarwal, Neeraj, Higano, Celestia S., Vogelzang, Nicholas J., Thompson, Ian M.
Publicado no Lancet Oncol (2013)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel

Por Cheng, Heather H., Gulati, Roman, Azad, Arun, Nadal, Rosa, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta K., Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia A., Montgomery, R. Bruce, Galsky, Matthew D., Antonarakis, Emmanuel S., Chi, Kim N., Yu, Evan Y.
Publicado no Prostate Cancer Prostatic Dis (2015)

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase 3 metastatic castration resistant prostate cancer trial

Por Goldkorn, Amir, Ely, Benjamin, Tangen, Catherine M., Tai, Yu-Chong, Xu, Tong, Li, Hongli, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Vogelzang, Nicholas J., Thompson, Ian M., Cote, Richard J., Quinn, David I.
Publicado no Int J Cancer (2014)

Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prosta...

Por Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Xu, Tong, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara, Primo, Higano, Celestia S., Hussain, Maha, Thompson, Ian Murchie, Cote, Richard J., Vogelzang, Nicholas J.
Publicado em 2014

A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma

Por Hussain, Maha, Daignault, Stephanie, Agarwal, Neeraj, Grivas, Petros D., Siefker-Radtke, Arlene O., Puzanov, Igor, MacVicar, Gary R., Levine, Ellis Glenn, Srinivas, Sandy, Twardowski, Przemyslaw, Eisenberger, Mario A., Quinn, David I., Vaishampayan, Ulka N., Yu, Evan Y., Dawsey, Scott, Day, Kathleen C., Day, Mark L., Al-Hawary, Mahmoud, Smith, David C.
Publicado em 2014

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Por Weiss, Glen J., Chao, Joseph, Neidhart, Jeffrey D., Ramanathan, Ramesh K., Bassett, Dawn, Neidhart, James A., Choi, Chung Hang J., Chow, Warren, Chung, Vincent, Forman, Stephen J., Garmey, Edward, Hwang, Jungyeon, Kalinoski, D. Lynn, Koczywas, Marianna, Longmate, Jeffrey, Melton, Roger J., Morgan, Robert, Oliver, Jamie, Peterkin, Joanna J., Ryan, John L., Schluep, Thomas, Synold, Timothy W., Twardowski, Przemyslaw, Davis, Mark E., Yen, Yun
Publicado em 2013